BioElectronics Responds to FDA’s 510(k) Additional Information Requests for its Musculoskeletal Pain Relief and Postoperative Pain Applications

FREDERICK, MD, April 23, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL), announced that the Company has submitted its response to the U.S. Food and Drug Administration’s (FDA) request for additional information on its ActiPatch® 510(k) market clearance application for “treatment of musculoskeletal pain in women”. Additionally, the Company has … Continue Reading

Northwest Specialty Hospital Now Offering Electroceutical Alternative To Opioids In Clinical Practice

PR Newswire POST FALLS, Idaho, March 14, 2019 POST FALLS, Idaho, March 14, 2019 /PRNewswire/ — Northwest Specialty Hospital is proud to announce that they are offering electroceutical devices as an alternative to opioid medication for pain management in conjunction with RiversEdge Orthopedics, Axis Spine and Bioelectronics Corporation (OTC PINK: BIEL). According to the National Institute on Drug Abuse, … Continue Reading

BioElectronics Announces Back Pain Clinical Study with Leading Australian Pain Center

Pulsed Shortwave Neuromodulation Therapy (ActiPatch®) Study in Chronic Lower Back Pain FREDERICK, MD, March 08, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL) http://www.bielcorp.comis pleased to announce the commencement of a clinical study investigating the efficacy of ActiPatch in treating chronic lower back pain. The objectives of this additional back pain study are … Continue Reading

BioElectronics Files FDA Applications for Treatment of Musculoskeletal & Postoperative Pain

FREDERICK, MD, Feb. 12, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL), is pleased to announce that two Traditional 510(k) Premarket Notification applications were filed with the U.S. Food and Drug Administration (FDA). The applications were for the ActiPatch® and RecoveryRx® medical devices for market clearances of “over-the-counter adjunctive treatment of musculoskeletal … Continue Reading

President’s Response to Stock Price Decline

Frederick, Maryland, Dec. 04, 2018 (GLOBE NEWSWIRE) – Dear Fellow Shareholders: While we were all disappointed by the dramatic drop in the stock price, it hasn’t had an impact on the Company’s operations. What is still needed is a cost-effective efficacious painkiller that is also an alternative to opioids. Physicians prescribe, and patients take opioids … Continue Reading

BioElectronics Announces FDA Market Clearance Update

FREDERICK, MD, Nov. 27, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced that the U.S. Food & Drug Administration (FDA) declined the company’s 510(k) submission for ActiPatch®, intended for seeking expanded over-the-counter (OTC) indications for the treatment of musculoskeletal pain. In the back pain … Continue Reading

BioElectronics Announces Publication of Electroceuticals Article on Chronic Pain

FREDERICK, MD, Oct. 04, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced the publication of an article in the October 2018 edition of the European Biopharmaceutical Review. Titled “Effective Electroceuticals,” the article provides insights into how electroceuticals (devices that provide electrical therapy) are set … Continue Reading

BioElectronics’ President Discusses ActiPatch’s® Opioid Application

PHOENIX, Sept. 11, 2018 (GLOBE NEWSWIRE) — President of BioElectronics Corporation (OTC Pink:BIEL) (“the Company”) goes back onto the “Stock Day” podcast. BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of the unique product line of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; … Continue Reading

BioElectronics Applies for FDA’s Opioid Alternative Innovation Challenge Program

FREDERICK, MD, Aug. 13, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL),, is pleased to announce that it has submitted an application to the U.S. Food and Drug Administration’s 2018 Opioid Innovation Challenge. This challenge was designed by the FDA to spur the development/deployment of medical devices that can help combat the opioid … Continue Reading

BioElectronics ActiPatch Musculoskeletal Therapy Added to Mundipharma Australia’s Pain Portfolio

FREDERICK, MD, July 23, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), is pleased to announce that Mundipharma Pty Limited (Mundipharma), has added ActiPatch® to its pain management portfolio, by acquiring the exclusive Australian and New Zealand distribution rights to the ActiPatch® Musculoskeletal Pain Therapy medical device. “The addition of ActiPatch® to our existing pain medications … Continue Reading